Search form

Intended Use For Research Use Only. Not for use in diagnostic procedures.
Catalog Number A239
Price $332.00 (U.S. List Price)
Size 100 µL
Application EIA, FACS, IHC, WB, IF
Buy Now         Request Info

Description

For Research Use Only. Not for use in diagnostic procedures.

A murine monoclonal antibody to a neoantigen on the terminal complement complex.

This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.

Quidel's TCC monoclonal antibody has been used in a variety of experimental techniques including EIA, Western Blot, and Immunohistochemistry. Please contact Quidel Technical Support for details on these or other applications.

References: 

8 References

TScambi C, Ugolini S, Jokiranta TS, De Franceschi L, Bortolami O, et al. (2015) The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study. PLOS ONE 10(2): e0114856.

Loeffler DA, Camp DM, Bennett DA. Plaque complement activation and cognitive loss in Alzheimer’s disease. Journal of Neuroinflammation. 2008;5:9.

Merri, A., Junnikala, S. Exceptional Resistance of Human H2 Gioblastoma Cells to Complement Mediated Killing by Expression and Utilization of Factor H and Factor H Like Protein 1, J Immunol 164:11 6075-6081, 2000.

Stoltzner, S., Lemerre, C. et al. Temporal accrual of complement proteins in Amyloid plaques in patients with down's syndrome with Alzheimer's Disease, Am J Path 156:489-499, 2000.

Wright, A., Morrison, S. Effect of C2 Associated Carbohydrate structure of Ig Effector function: studies with chimeric mouse human IgG1 Antibodies in glycosylation mutants of chinese hamster ovary cells, J. Immunol 160:3393-3402, 1998.

Gemmell, C. A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces, J Biomed Mater Res 37, 474-480, 1997.

Rogers, J., N. Cooper, et al. Complement Activation by ß-amyloid in Alzheimer disease, PNAS 89:10016-10020, 1992.

Depisch, R. V. Schmitt et al. Fluid phase generation of terminal complement complex as a novel index of bio-incompatibility, Kidney Int'l, 37, 696-627 1990.

Features & Benefits

FeatureBenefit

Product Specifications

Product Spec NameProduct Spec Data
Isotype

IgG2ak

Protein concentration

> 1.0 mg/mL

Volume/vial

100 µL

Storage

2°C to 8°C

Ordering Information

Catalog NumberKit Size / Case Size
A239
100 µL

Product Documentation

Product documentation is best viewed in Internet Explorer
Accept
By continuing to use this site you are agreeing to our use of cookies. For more details please see our Privacy and Cookie Notice.